🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
17.58
-0.96 (-5.18%)
At close: Nov 20, 2026, 4:00 PM EST
18.00
+0.42 (2.39%)
After-hours: Nov 20, 2026, 7:30 PM EST

Caris Life Sciences Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, Caris Life Sciences stock has a consensus rating of "Buy" and an average price target of $34.23. The average 1-year stock price forecast is 94.71% higher than the current stock price, while the lowest is $25 (+42.21%) and the highest is $38 (+116.15%).

Price Target: $34.23 (+94.71%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$25$34.23$35$38
Change+42.21%+94.71%+99.09%+116.15%

Analyst Ratings

The average analyst rating for Caris Life Sciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy999999
Buy111111
Hold333444
Sell000000
Strong Sell000000
Total131313141414

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Piper Sandler
Piper Sandler
Hold
Reiterates
$22 → $25
HoldReiterates$22 → $25+42.21%Nov 10, 2026
Unknown Analyst
Guggenheim
No rating
Guggenheim
Buy
Reiterates
$36
BuyReiterates$36+104.78%Nov 10, 2026
Albert Hu
Citi
Citi
Buy
Maintains
$28 → $36
BuyMaintains$28 → $36+104.78%Nov 6, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
n/a
BuyMaintainsn/an/aNov 5, 2026
Canaccord Genuity
Canaccord Genuity
Hold
Maintains
$30
HoldMaintains$30+70.65%Nov 5, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.05B
from 812.03M
Increased by 28.81%
Revenue Next Year
1.25B
from 1.05B
Increased by 19.11%
EPS This Year
0.12
from -0.41
EPS Next Year
0.30
from 0.12
Increased by 163.36%
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026E
Period EndingDec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
258.49M306.13M412.26M812.03M1.05B
Revenue Growth
-18.43%34.67%96.97%28.81%
Gross Profit
80.02M91.26M180.43M541.04M693.14M
Gross Margin
30.96%29.81%43.77%66.63%66.27%
Operating Income
-315.76M-319.55M-257.12M45.11M91.97M
Net Income
-320.83M-341.42M-281.89M-68.09M32.98M
EPS
----0.410.12
Forward PE
---294.73152.29
Free Cash Flow
---66.90M-51.93M
No. Analysts
----12
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High1.1B
Avg1.0B
Low1.0B

Revenue Growth

Revenue Growth202620272028
High
31.0%
Avg
28.8%
Low
28.2%

EPS Forecast

EPS202620272028
High0.17
Avg0.12
Low0.09

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-